Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Open Label Study of the Pre- and Postoperative Use of ZD1839 (Iressa) in Recurrent Glioblastoma, Including Translational Research

NCT00250887 is registered in ClinicalTrials.gov with University of Zurich as lead sponsor.

NCT NCT00250887
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00250887 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Open Label Study of the Pre- and Postoperative Use of ZD1839 (Iressa) in Recurrent Glioblastoma, Including Translational Research
Lead sponsor
University of Zurich
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2005
Completion date
May 31, 2007
Enrollment
22 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent glioblastoma